Purpose: To describe lipoatrophy of the plantar pedis fat pads in human immunodeficiency virus (HIV) patients with or without long-term antiretroviral therapy (ART); to compare the characteristics of ART patients with and without plantar pedis lipoatrophy; and to examine the effects of HIV and metabolic/cardiovascular risk parameters and treatment history on plantar pedis lipoatrophy. Design: Participants included 134 patients who started protease inhibitors in antiretroviral therapy (ART) in 1996 and 49 treatment-naive patients, recruited in 2004. Participants were examined and graded for lipoatrophy of five body compartments including the plantar fat pads. Baseline HIV-and ART-related factors were documented together with follow-up metabolic/ cardiovascular risk parameters. Results: Plantar pedis lipoatrophy occurred more often among ART patients (60%) than among treatment-naive patients (12%; p < .001). ART patients with plantar lipoatrophy were older, had higher plasminogen activator inhibitor 1 (PAI-1) values, a higher prevalence of lipoatrophy in other body compartments, and longer stavudine and didanosine treatment history as compared to patients without plantar lipoatrophy. Multiple logistic regression modeling revealed that among the metabolic/cardiovascular parameters, increased PAI-1 was strongly and positively associated with plantar lipoatrophy. Among the treatment history parameters, didanosine was the strongest independent predictor for plantar lipoatrophy. Increased PAI-1 was not associated to lipoatrophy in any other location. Conclusions: Plantar lipoatrophy is common among patients on long-term ART and, though often overlooked, may cause significant discomfort. The association to PAI-1, a well-known marker of increased cardiovascular risk, is intriguing and places further focus on the need for an active approach to evaluating and lowering cardiovascular risk factors in long-term HIV treatment.
Since the introduction of protease inhibitors (PI) in antiretroviral therapy (ART) in 1996, the mortality rate and incidence of AIDS-related conditions have declined dramatically (Mocroft et al., 2003) . However, ART is itself associated with metabolic abnormalities including hyperlipidemia, insulin resistance, and subcutaneous and visceral lipodystrophy. The degree of lipodystrophy (loss of subcutaneous fat and the accumulation of visceral fat) is in daily clinical life generally assessed via subjective observation by the patient and/or clinician. ART-associated lipodystrophy has been reported in 11-83% of patients receiving ART (Carter et al., 2001; Grinspoon & Carr, 2005; Hansen et al., 2006; Mauss et al., 2002) , and several studies have suggested that lipodystrophy is negatively associated with health-related quality of life (Guaraldi et al., 2008; Nicholas, Kirksey, Corless, & Kemppainen, 2005) and/or adherence to therapy (Guaraldi et al., 2008) .
There is increasing evidence that separate mechanisms may be responsible for the subcutaneous lipoatrophy and the often coexisting absolute or relative abdominal lipohypertrophy, which is often combined with increased fat in the liver (Grinspoon & Carr, 2005; Saint-Marc et al., 1999) . Peripheral lipoatrophy has been correlated to older age, advanced disease stage, longer duration of ART, and the nucleoside analogue reverse transcriptase inhibitors (NRTI) stavudine, didanosine, and zidovudine (Carr et al., 1998; Lichtenstein, 2005 The pathogenic mechanisms suggested for lipoatrophy include deranged fat cell differentiation or apoptosis and mitochondrial toxicity (Lichtenstein, 2005) . Stavudine, didanosine, and, to some extent, zidovudine interfere with mitochondrial gamma polymerase (Villarroya, Domingo, & Giralt, 2005) . Fat biopsies from patients on NRTI-containing ART have been shown to have lower mitochondrial DNA content and RNA expression (Mallon et al., 2008) . With the exception of atazanavir, PIs inhibit lipogenesis and adipocyte development, increase lipolysis, and induce insulin resistance directly through the inhibition of glucose transport into the cell and indirectly through abdominal obesity (Grinspoon & Carr, 2005; Moyle, 2007; Murata, Hruz, & Mueckler, 2002; Noor, Flint, Maa, & Parker, 2006) . Also NRTIs have been found to decrease insulin sensitivity, possibly due to increased lipolysis (Blumer et al., 2008) .
Plasminogen activator inhibitor type 1 (PAI-1) is an important inhibitor of fibrinolysis, contributes to the pathogenesis of atherosclerosis, and is a well-known risk factor for coronary artery disease (Kohler & Grant, 2000) . Increased PAI-1 has been reported in lipodystrophy (He et al., 2005) and seems to be linked to the insulin resistance (De Larranaga, Galich, Puga, Alonso, & Benetucci, 2004). Furthermore, PAI-1 is possibly produced, together with other cardiovascular risk factors, in the fatty liver (Yki-Jarvinen, 2005).
In our clinical practice, we have made a new observation in patients on ART reporting non-neuropathic foot pain while walking and standing. Some of these patients display a pronounced reduction of the plantar pedis fat pads. However, apart from case reports (Stupar & Tibbles, 2008) , no systematic studies have been published investigating the prevalence of plantar lipoatrophy and its contributing factors. The purposes of this study, then, were (a) to describe and compare the prevalence of lipoatrophy of the plantar pedis fat pads in long-term ART patients and ART-naive patients, (b) to describe and compare the characteristics of human immunodeficiency virus (HIV)infected patients with and without lipoatrophy of the plantar pedis fat pads, and (c) to examine the influence of baseline clinical characteristics, current metabolic and cardiovascular risk parameters, and treatment history on lipoatrophy of the plantar pedis fat pads in ART patients.
Material and Method Patients
Treatment with PIs in the form of indinavir TID or ritonavir BID was introduced at Venhälsan HIV Clinic, Stockholm South General Hospital, Stockholm, in 1996. All 202 patients who started PI-ART in 1996 were included in a clinical cohort to be monitored prospectively. During 2004, the 160 patients remaining from this cohort (ART patients; 30 patients had died and 12 had moved to another city or country) together with an additional 89 consecutive treatment-naive HIV-positive patients (ART-naive control group) visiting the clinic for their routine checkup were invited to participate in the current study. All potential participants received oral and written information about the current study by their responsible staff nurse. Those who agreed to participate were asked to sign a consent form. The patients were asked to give blood samples for the analyses specified below and to have a physical examination for potential lipoatrophy by a plastic surgeon not involved in their care. The study procedures and research instruments were reviewed and approved by an institutional ethics committee (South Review Board of Research Ethics, Huddinge University Hospital).
Measurements
Lipoatrophy. The plastic surgeon performed a systematic physical examination with ''fat mapping,'' including an inhouse standardized grading of the degree of subcutaneous fat wasting in the following regions: face, gluteal regions, thigh, palm, and sole of the foot. The degree of regional lipoatrophy was rated on a 0-5 scale. In addition, the body mass index (BMI) and waist-hip ratio (WHR) were calculated.
Baseline clinical characteristics. For the ART patients, data at baseline (i.e., at PI-ART start, year 1996) on age, time since HIV diagnosis, AIDS diagnosis, NRTI experience at the start of PI, HIV-RNA (Roche ultra-sensitive test, version 1.5; frozen samples), and CD4 cell count were obtained by review of medical records. Furthermore, the history of ART with the exact treatment time in days on each individual drug was calculated.
Current CD4, metabolic and other cardiovascular risk parameters. All blood was sampled during morning hours with the patients fasting since midnight. CD4 cell measurements were performed by the Swedish Institute for Infectious Disease Control (lyse-no-wash preparation and ''single-platform'' procedure with reagents from Becton Dickinson, Hägersten, Sweden). All other laboratory tests were performed by the Laboratory of Clinical Chemistry at Huddinge University Hospital (accreditation by the Swedish Board for Accreditation and Conformity Assessment) with standard biochemical methods where not otherwise indicated.
The fasting plasma levels of glucose and insulin were determined. The homeostatic model assessment for insulin resistance (HOMA-IR) was calculated using the formula [HOMA-IR ¼ (insulin (pmol/l) / 6.945 Â glucose (mmol/l)) / 22.5]. A HOMA-IR index above 3 indicates insulin resistance. Triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (Apo A1), apolipoprotein B (Apo B), and lipoprotein (a) (Lp[a]) were determined. Low-density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald formula. High-sensitivity C-reactive protein (hsCRP) was determined. The plasma level of PAI-1 was determined on citrated plasma with the Chromolize PAI-1 kit (Biopool AB, Umeå, Sweden).
Statistical Methods
Statistical analyses were performed with SPSS for Windows, version 13.0. The criterion for accepting statistical significance was p < .05. The nonparametric Mann-Whitney U test was used for pairwise group comparisons of continuous and scaled variables. Fisher's exact test was used for group comparisons on frequency data. Logistic regression analyses were performed to study the influence of different potentially related variables on the odds ratio (OR) for development of lipoatrophy of the plantar fat pads among the patients up to 8 years after start of PI-ART (follow-up). First, the influence of each independent variable on the dependent variable was analyzed univariately. Subsequently, those independent variables statistically significant in the univariate analysis were entered simultaneously in a multiple logistic regression. The independent variables investigated were a set of potential risk factors at baseline and the outcome of the different relevant metabolic and cardiovascular risk parameters at follow-up. In a second set of analyses, the influence of treatment with didanosine and stavudine on the OR for development of lipoatrophy of the plantar fat pads was performed. The independent variables were dichotomized as follows: age was coded into the lowest quartile (i.e., the youngest patients) versus the other three quartiles; HIV-RNA at baseline was coded as <100,000 copies/ml versus !100,000 copies/ml; CD4 count and time with known HIV infection at baseline were coded as versus > group median values; the metabolic and cardiovascular risk parameters at follow-up were coded according to the laboratory's reference values (i.e., normal vs. pathological); the follow-up Lp(a) was coded as > or 300 mg/l; the follow-up HOMA-IR index was coded as < or !3. Treatment with didanosine and stavudine were coded as ever treated or never treated with the respective drug. Lastly, to study the association between abnormal PAI-1 and lipoatrophy of all investigated body regions, a multiple logistic regression analysis was performed with PAI-1 as the dependent variable and lipoatrophy in face, gluteal regions, thigh, palm, and sole of the foot as the independent variables.
Results

Study Participant
The majority of both ART patients and the ART-naive control patients approached agreed to take part in the study (134/160 [84%] ART patients: 125 men who have sex with men [MSM], 7 women, and 2 heterosexual men; 49/89 [55%] ART-naive patients: 48 MSM and 1 heterosexual man). Comparisons between participants and nonparticipants within the ART group and the ART-naive control group regarding age, AIDS, CD4, HIV-RNA, and months since HIV diagnosis did not show any statistically significant differences (data not shown).
Baseline Characteristics of the ART Patients
At PI-ART start (year 1996; n ¼ 134) the median age of patients in the ART group was 39. 5 
Comparisons of Demographic, Clinical, and Metabolic Characteristics
Comparisons regarding the ART and the ART-naive control patients' demographic, clinical, and metabolic characteristics at follow-up are shown in Table 1 . Not surprisingly, the ART patients were older and had longer known time with HIV infection as compared to the ART-naive patients. The ART patients had lower weight and BMI and higher WHR than the ARTnaive patients. When comparing the metabolic and cardiovascular risk laboratory parameters, the ART patients had higher levels of both the ''bad'' lipids TG, TC, LDL-C, and Apo B and the ''good'' lipids HDL-C and Apo A1. Furthermore, HOMA-IR was higher among the ART patients, suggesting a higher degree of insulin resistance among the patients on treatment.
Prevalence of Lipoatrophy of the Plantar Pedis Fat Pads
Lipoatrophy of the plantar pedis fat pads was found in 81/134 (60%) of the ART patients as compared to 6/49 (12%) of the ART-naive control patients (p < .001). Half (3/6) of the ART-naive patients with plantar pedis lipoatrophy had HOMA above 3, indicating insulin resistance.
Prevalence of Lipoatrophy in Locations Other Than the Plantar Pedis
Lipoatrophy of the hand was found in 44/134 (33%) of the ART patients and 4/49 (8%) of the ART-naive control patients (p < .001), gluteal lipoatrophy was found in 68/134 (51%) of the treated and none of the naive patients (p < .001), thigh lipoatrophy was found in 69/134 (51%) of the treated and 3/49 (6%) of the naive patients (p < .001), and face lipoatrophy was found in 48/134 (36%) of the treated and 1/49 (2%) of the naive patients (p < .001).
Comparison Between the ART Patients With and Without Plantar Pedis Lipoatrophy
Comparisons between the ART patients with and without plantar pedis lipoatrophy are shown in Table 2 . The patients with plantar lipoatrophy were older and had higher PAI-1 values, indicating a more atherogenic profile as compared to the patients without plantar lipoatrophy. When comparing treatment time on different individual drugs, the patients with plantar lipoatrophy had been on didanosine and stavudine longer than those without plantar lipoatrophy. Not surprisingly, the patients with plantar lipoatrophy also had a higher prevalence of lipoatrophy of the other investigated body compartments as compared to the patients without plantar lipoatrophy.
Effects of Baseline Clinical Characteristics and Current Parameters on Plantar Pedis Lipoatrophy Among ART Patients
The results of the univariate logistic regression analyses to investigate the effects of baseline clinical characteristics and current metabolic and cardiovascular risk parameters on plantar pedis lipoatrophy are shown in Table 3 . Only baseline CD4 count below median and currently abnormal PAI-1 (i.e., above 15 kIU/l) were statistically significantly associated with lipoatrophy of the plantar pedis fat pads. The OR for having plantar pedis lipoatrophy was 2.13 for those having a baseline CD4 count below median as compared to those having a baseline CD4 count above median. Further, the OR for having plantar pedis lipoatrophy was 2.69 for those having abnormal PAI-1 as compared to those having PAI-1 within the normal range (i.e., below 15 kIU/l). There was no statistically significant association with NRTI experience at PI-ART start, disease stage, age, HIV-RNA, months with HIV infection, lipid values, HOMA-IR, or hsCRP. In the multivariate logistic regression analysis, when baseline CD4 count and current PAI-1 were entered simultaneously into the equation, only PAI-1 showed a statistically significant association to plantar pedis lipoatrophy. When the effect of baseline CD4 count was adjusted for, the OR for having plantar pedis lipoatrophy was 2.52 for those having abnormal PAI-1 as compared to those having PAI-1 within the normal range.
Effects of Treatment History With Different Antiretroviral Drugs on Plantar Pedis Lipoatrophy Among ART Patients
When the effects of treatment with didanosine and stavudine were investigated in univariate logistic regression analyses, treatment history with didanosine showed a statistically significant association with plantar pedis lipoatrophy. The OR for having plantar pedis lipoatrophy was 3.12 for those having a treatment history with didanosine as compared to those without a treatment history with didanosine ( Table 3 ).
The Effects of Lipoatrophy at Various Locations on Increased PAI-1 Among ART Patients
As abnormal PAI-1 was the strongest predictor of plantar pedis lipoatrophy and there was a relation between plantar pedis lipoatrophy and lipoatrophy in the other investigated body regions, a multivariate logistic regression analysis was performed to investigate the effect of lipoatrophy of all investigated body regions on the OR for having an abnormal PAI-1. The result showed that only plantar pedis lipoatrophy had a statistically significant effect on the OR for having abnormal PAI-1. The OR for having abnormal PAI-1 was 2.92 for those having plantar pedis lipoatrophy as compared to those not having plantar pedis lipoatrophy when the effects of lipoatrophy at the other investigated locations were adjusted for ( Table 4 ).
Discussion
In this cross-sectional study, the vast majority of the HIVinfected patients on long-term ART had a reduction of the plantar pedis fat pads. HIV-associated lipoatrophy of this particular region has, to our knowledge, not been systematically described before. Furthermore, the study also revealed a high prevalence of lipoatrophy in other body regions.
The ART patients with plantar lipoatrophy were characterized by higher age, higher PAI-1, higher prevalence of lipoatrophy in other regions, and longer didanosine and stavudine exposure than the ART patients without plantar lipoatrophy. In the multivariate logistic regression analysis including HIV and metabolic parameters, the best predictive model for plantar pedis lipoatrophy was increased PAI-1. Although thinning of the plantar fat pads has been described in non-HIV-infected diabetic patients with polyneuropathy (Bus, Maas, Cavanagh, Michels, & Levi, 2004), we did not find any association to insulin resistance among the ART patients. However, plantar pedis lipoatrophy was also found in 12% of the ART-naive patients, half of whom had signs of insulin resistance.
Autopsy studies have shown the fat pads of the feet to have a significant nerve and blood supply separate from the surrounding musculature and a meshwork of septa arranged in closedcell configuration, creating a delicate weight-bearing structure (Jahss et al., 1992) . It is likely that the fat hypotrophy found in this study impairs this cushioning function. The consequences for the patient might be pain and stiffness while standing and walking.
HIV infection, both before and after the introduction of PI-ART, is associated with a pro-atherogenic lipid profile characterized by an increase in triglyceride levels, a decrease in HDL-C, and the presence of small LDL-C particles (Riddler et al., 2003; Salyer, Lyon, Settle, Elswick, & Rackley, 2006) . Hansen and colleagues (2006) found that patients on ART for 6 years had decreased HDL-C and BMI and increased TG and insulin values as compared to HIV-negative healthy controls. In the current study, we found that the ART patients had higher triglycerides, LDL-C, and HOMA-IR indices and lower BMI as compared to the ART-naive HIV-positive controls. However, we found the HDL-C and ApoA1 levels to be higher among the ART patients, possibly reflecting treatment-induced reversion of HIV-induced lipid abnormalities.
PAI-1, but not triglycerides, hsCRP, or HOMA was associated with plantar pedis lipoatrophy. No association of increased PAI-1 was found to lipoatrophy in any other location. Abdominal and liver fat are important sources of PAI-1 (Alessi et al., 1997; Yki-Jarvinen, 2005). PAI-1 is increased in patients Certain study limitations should be emphasized when interpreting these results. Firstly, the great majority of the investigated cohort was male patients who started PI-ART in an advanced stage of HIV infection and had prior experience of NRTI mono or dual therapy. The inferences drawn from this study might not be applicable to women or to ART-naive patients starting ART today in a less advanced stage of the disease and with more metabolically tolerable combinations. With regard to gender, however, a recent study has shown that lipodystrophy is at least as common if not even more so (including fat loss from lower limbs) in women (Galli et al., 2003) , suggesting that the present study findings may be of importance for both sexes. Secondly, as expected, the treatment-naive control group was younger and had had shorter known time with HIV infection as compared to the ART patients. However, a comparison with an HIV-positive control group may have an advantage in sorting out more specific ART-related effects in contrast to using a matched HIV-negative control group. Thirdly, there were some problems motivating the naive controls to participate in the study. However, there were no apparent demographic or clinical differences between the participating and nonparticipating control patients.
Conclusion
Evaluation of the plantar pedis fat pads in patients on ART should be performed regularly by the responsible physician or nurse specialist, especially when there are signs of lipoatrophy in other areas and regardless of any spontaneously reported leg or foot discomfort. Because of the proposed relation to increased cardiovascular risk, the presence of plantar lipoatrophy and/or foot pain might also indicate the need for cardiovascular risk reduction interventions. Furthermore, the presence of plantar pedis lipoatrophy should actualize the need to reconsider the patient's ART regimen with the goal of avoiding zidovudine, didanosine, and stavudine whenever possible. Further research about the causes of plantar pedis lipoatrophy is needed to prevent and relieve patients' suffering. The strong association with PAI-1 suggests possible treatment options with anticoagulants and/or drugs that decrease liver and central fat accumulation. 
